Creatinine is a breakdown product of creatine phosphate in muscle, filtered by the kidneys at a relatively constant rate. It serves as a key marker of kidney function and estimated glomerular filtration rate (eGFR). However, creatinine has important limitations: it's a lagging indicator (serum creatinine doesn't rise until GFR drops roughly 50%), it reflects muscle mass as much as kidney function, and dietary protein intake and certain medications can distort results.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring of renal function. Not a stand-alone diagnosis.
If you have diabetes, hypertension, a family history of chronic kidney disease, or are taking medications that affect kidney function, monitoring creatinine is important for detecting early renal decline. Creatinine testing is a standard component of health screening, though interpreting it correctly requires accounting for age, sex, muscle mass, and diet.
Beyond detecting kidney disease, creatinine helps guide medication safety—certain drugs (ACE inhibitors, NSAIDs, metformin) require dose adjustment if kidney function declines. It also contextualizes muscle metabolism and can flag excessive protein catabolism in older adults or athletes.
Estimates glomerular filtration rate (GFR). Creatinine is the basis for eGFR calculation, which estimates how much blood your kidneys filter per minute—the gold-standard measure of kidney function.
Detects kidney dysfunction early. Rising creatinine over time signals declining renal clearance, even if values remain in the “normal” range—a crucial signal for proactive monitoring.
Guides medication safety. Knowing your renal function helps clinicians adjust doses of drugs metabolized by the kidneys and avoid nephrotoxins (NSAIDs, aminoglycosides, contrast agents).
Contextualizes muscle metabolism. Creatinine production is proportional to muscle mass, so tracking trends helps distinguish between muscle loss and true kidney dysfunction—particularly important in aging and chronic disease.
Reveals medication or dietary confounders. Abnormal creatinine may reflect trimethoprim use, cimetidine, recent heavy meat consumption, or dehydration rather than kidney disease, requiring interpretation alongside clinical context.
Works as a screening marker. Combined with cystatin-c or urea, creatinine provides a multi-angle view of renal function and helps identify discordance that might suggest atypical muscle mass or metabolic issues.
Origin and filtering. Creatinine is produced at a steady rate by muscle cells as creatine phosphate breaks down during energy metabolism. The amount produced daily is proportional to total muscle mass—athletes and muscular individuals produce more creatinine than sedentary or elderly people with equivalent kidney function. Once produced, creatinine is filtered almost entirely by the kidneys through glomerular filtration. Unlike many other waste products, the kidneys don't actively reabsorb or metabolize creatinine, making it a fairly stable marker of filtration rate.
Why it lags and misleads. The relationship between kidney function and serum creatinine is not linear. When GFR drops to 50% of normal, creatinine may still be “normal” because the remaining nephrons increase their filtration rate per unit (hyperfiltration). Creatinine only begins to rise noticeably when GFR falls below 50 mL/min/1.73m²—meaning a person can lose half their kidney function and creatinine may not flag it. This is why creatinine-based eGFR can miss early chronic kidney disease (CKD).
The muscle mass problem. Because creatinine production depends on muscle mass, a 75-year-old woman with sarcopenia may have a “normal” creatinine (say, 65 µmol/L) despite a GFR of 35 mL/min—her low muscle mass masks kidney dysfunction. Conversely, a 30-year-old bodybuilder may have creatinine of 110 µmol/L with a GFR of 100 mL/min—his high muscle mass inflates the value. This discordance between creatinine and true kidney function is why cystatin-c (which is not muscle-mass-dependent) or combined eGFR estimates (which adjust for age and sex) often outperform creatinine alone.
Early detection of declining kidney function. Even without overt kidney disease, a rising creatinine trend over years reflects progressive nephron loss and is associated with increased cardiovascular and all-cause mortality risk in epidemiological studies. Early detection allows intervention (blood pressure control, lifestyle modification) before irreversible damage.
Drug safety and personalized dosing. Many medications commonly used in cardiovascular and metabolic health are renally cleared or nephrotoxic: ACE inhibitors, ARBs, SGLT2 inhibitors, metformin, NSAIDs, statins. Knowing your GFR (calculated from creatinine) prevents drug accumulation and toxicity.
Reveals metabolic phenotype. Creatinine production directly reflects muscle protein turnover. Combined with urea (which reflects dietary protein intake and catabolism), creatinine helps distinguish true kidney disease from muscle wasting, overtraining, or severe caloric restriction—all of which distort the picture in isolation.
Contextualizes fitness and aging. A stable or rising creatinine in an older adult with declining muscle mass is worrying; in a younger athlete, elevation reflects adaptation. Tracking creatinine over time against changes in strength and body composition tells a fuller story of renal reserve and metabolic health.
Standard Swedish healthcare reference (vårdcentralen): Men 60–105 µmol/L; women 45–90 µmol/L (lab-dependent; always check local reference range).
Loovi proactive (longevity): Men < 95 µmol/L; women < 80 µmol/L. This range reflects younger kidney function and leaves room for age-related decline without crossing into early CKD territory.
Cautionary zone (may warrant investigation): Men 105–130 µmol/L; women 90–110 µmol/L. Not “abnormal,” but especially in those over 40, rising toward these levels warrants eGFR calculation and trend review. Calculate eGFR using creatinine, age, and sex (or cystatin-c if muscle mass is atypical).
Creatinine > 130 µmol/L in men or > 110 µmol/L in women warrants full kidney evaluation. Remember: an isolated “normal” creatinine does not rule out early kidney disease, especially in older or lean individuals. Always interpret alongside eGFR, cystatin-c, and urea.
Low creatinine (< 45 µmol/L). Low creatinine typically reflects low muscle mass—common in sedentary older adults, those with chronic illness, or individuals with severe sarcopenia. In younger, fit people, it can be normal. Low creatinine alone is not “bad,” but combined with low or declining strength, it flags muscle loss that may accelerate metabolic decline. It does not indicate good kidney function if muscle mass is depressed. Calculate eGFR; a low creatinine coupled with low eGFR confirms early kidney disease, which is the real concern. Monitor for progression and investigate causes of muscle wasting (protein-calorie malnutrition, chronic inflammation, endocrine dysfunction).
Optimal creatinine (45–90 µmol/L for women; 60–95 µmol/L for men). This range reflects healthy kidney filtration and adequate muscle mass in most individuals. If you're in this range and creatinine is stable over years, kidney function is likely preserved. In younger, very muscular individuals, values at the high end of this range are physiologic. In older or leaner individuals, values at the low end are normal. The key is stability: rising creatinine even within the “normal” range signals declining kidney function and deserves follow-up.
High creatinine (95–130 µmol/L for men; 80–110 µmol/L for women). Elevated creatinine may reflect true kidney dysfunction (hypertension, diabetes, glomerulonephritis, obstructive nephropathy) or high muscle mass in athletes and muscular individuals. Distinguishing requires eGFR calculation and, critically, cystatin-c testing. If eGFR is normal (> 60 mL/min/1.73m²), high creatinine likely reflects muscle mass and is not pathologic. If eGFR is low and cystatin-c is also elevated, true kidney disease is present. Investigate causes: blood pressure control, urinalysis (proteinuria?), glucose control, medication effects (NSAIDs, ACE inhibitor dose-response), and family history of CKD.
Very high creatinine (> 130 µmol/L in men; > 110 µmol/L in women). This warrants urgent evaluation for kidney disease unless you have very high muscle mass (elite athletes). Calculate eGFR immediately and order cystatin-c, urinalysis, and renal ultrasound if eGFR < 60 mL/min/1.73m². Very high creatinine with normal eGFR is unusual and suggests either analytical error, extreme muscle mass, or muscle rhabdomyolysis (exercise, statins, rare genetic myopathy).
Factors that influence creatinine. Acute or chronic illness, dehydration, intense exercise within 48 hours, high dietary protein intake (especially cooked red meat 24 hours before testing), medications blocking tubular secretion (trimethoprim, cimetidine), aging (muscle loss), female sex (lower baseline muscle mass), pregnancy (GFR increases, creatinine drops), certain statins and NSAIDs, and urinary retention all affect creatinine. Fasting is not required, but hydration status and timing relative to protein intake and exercise matter.
Chronic kidney disease (CKD). Progressive loss of nephron mass from diabetes, hypertension, autoimmune glomerulonephritis, or obstructive uropathy causes creatinine to rise. Early CKD (stages 1–2) may not raise creatinine at all; by stage 3 (GFR 30–59), creatinine is reliably elevated. Later stages (4–5) show marked elevation and require specialist management.
Muscle mass variation. Athletes and very muscular individuals naturally produce more creatinine per unit of kidney function; sedentary and elderly individuals produce less. This is the primary reason creatinine alone is misleading. Sex-specific reference ranges and age adjustment via eGFR formulae (CKDEPI or 2021 KDIGO) partially correct for this but don't eliminate the bias.
Medications and dietary factors. Trimethoprim and cimetidine block tubular secretion of creatinine, raising serum levels without reducing true GFR (a false elevation). High dietary protein intake, especially red meat cooked at high temperatures, transiently raises creatinine. This normalizes within 24–48 hours of dietary reset. NSAIDs, ACE inhibitors, and ARBs can cause acute creatinine elevation if they reduce glomerular filtration pressure (concerning if creatinine rises > 30% acutely).
Dehydration and acute kidney injury (AKI). Reduced renal perfusion from dehydration, severe illness, sepsis, or volume loss causes acute creatinine elevation. Unlike chronic CKD, AKI is reversible if the cause is corrected quickly. Creatinine can lag behind the rise in BUN (blood urea nitrogen), so paired testing helps distinguish.
Age and hormonal status. Aging reduces both muscle mass and kidney function; creatinine often rises with age even if GFR (adjusted for age) is stable. Menopause and androgen deficiency reduce muscle mass, lowering baseline creatinine and potentially masking early kidney disease. Pregnancy increases GFR, lowering creatinine transiently.
Preserve and build muscle mass. Resistance training and adequate protein intake (1.6–2.2 g/kg/day for older adults and those at CKD risk) preserve muscle mass and creatinine production, preventing false-low creatinine that masks kidney disease. Unlike interventions that lower creatinine itself, this approach maintains metabolic resilience.
Control blood pressure rigorously. Hypertension is the leading modifiable cause of CKD progression. ACE inhibitors and ARBs slow decline in GFR and reduce proteinuria in diabetic and non-diabetic CKD; optimal BP targets (usually < 130/80 mmHg in those with CKD or albuminuria) reduce creatinine rise over years.
Optimize glucose control. Diabetes causes progressive glomerulosclerosis and drives creatinine upward. Tight glycemic control (HbA1c < 7% in most; individualized targets in older adults) slows decline. GLP-1 receptor agonists and SGLT2 inhibitors provide additional kidney protection beyond glucose lowering.
Reduce nephrotoxic exposures. Chronic NSAID use accelerates renal decline, especially in those over 60 or with baseline CKD. Statins are generally renal-protective. Limit high-dose contrast exposure. Avoid dehydration, particularly around intense exercise or in hot climates. Monitor creatinine within 3–5 days of any new ACE inhibitor, ARB, or SGLT2 inhibitor dose to catch acute GFR drops.
Manage dietary protein thoughtfully. Very high protein intake (> 2.5 g/kg/day) may accelerate renal decline in those with CKD, though normal protein intake (1.2–1.6 g/kg/day) in healthy kidneys is safe. Avoid protein powders and meat supplements just before creatinine testing if you want a stable baseline.
The most powerful levers are blood pressure control, glycemic management, and muscle preservation. Whether creatinine rises, stays flat, or falls depends on your kidney function trajectory and muscle mass—which is why a single creatinine value is nearly meaningless. Trends matter far more, and they're best interpreted alongside eGFR, cystatin-c, and urea.
Creatinine alone is a blunt tool. A “normal” creatinine doesn't rule out kidney disease if you have low muscle mass; an “elevated” creatinine doesn't confirm kidney disease if you're very muscular or ate a steak yesterday. To interpret creatinine correctly, you need eGFR (which adjusts for age and sex), cystatin-c (which is independent of muscle mass and catches early kidney dysfunction creatinine misses), and urea (which reflects protein catabolism and helps distinguish true kidney disease from other causes of elevated creatinine). Ideally, you also want urinalysis to check for proteinuria and hematuria—both of which signal kidney damage even if creatinine is “normal.”
The Loovi Membership tracks 120+ biomarkers annually, including creatinine, eGFR, cystatin-c, urea, and urinalysis. This multi-angle approach catches early kidney dysfunction, distinguishes muscle mass from true disease, and flags medication effects before they cause harm. Paired with unrushed consultations with longevity doctors and drop-in access to 80+ Swedish clinics, you get the full renal picture—not just an isolated number. From 295 SEK/month, Loovi includes all testing, personalized guidance on kidney-protective interventions, and ongoing monitoring to prevent decline.
This pattern suggests early kidney decline that creatinine has not yet flagged, especially if you have low muscle mass. Cystatin-c, being independent of muscle, is often more sensitive to early GFR loss, particularly in elderly or sedentary individuals. Calculate eGFR using cystatin-c; if it's < 60 mL/min/1.73m², you have early CKD and should undergo full renal evaluation (ultrasound, urinalysis, blood pressure optimization). This pattern is not rare and highlights why creatinine alone misleads.
High creatinine with a normal eGFR (> 60 mL/min/1.73m²) almost always reflects high muscle mass rather than kidney disease. Confirm with cystatin-c (which should also be normal) and urinalysis (which should show no proteinuria or hematuria). If you're an athlete or very muscular, this is reassuring. If you're not particularly muscular, order cystatin-c to clarify whether the high creatinine reflects true kidney function loss masked by the eGFR formula.
Yes. Heavy red meat consumption, especially cooked meat, transiently raises serum creatinine within 24 hours and can increase it by 10–15 µmol/L in sensitive individuals. This reflects the creatine content of meat and the creatinine produced during cooking (heterocyclic amines). The elevation is temporary and resolves within 24–48 hours of normal diet. This is why timing matters: measure creatinine when your dietary intake is habitual, not after a single high-meat meal, or note the timing when interpreting results.
Yes. Creatinine and eGFR are part of standard health screening, and early CKD is often asymptomatic. Hypertension, even mild, drives kidney decline; diabetes does too. Even without family history, age, lifestyle (smoking, high alcohol, chronic inflammation), and medications (NSAIDs) affect kidney function. Baseline testing at age 30–40 and regular monitoring (annually after 50, or every 2 years if you're younger and healthy) catches decline early when intervention is most effective.
Creatinine is muscle-mass-dependent; cystatin-c is not. In people with typical muscle mass, they're similar. In older adults, athletes, or those with sarcopenia, they diverge. Cystatin-c is more accurate for detecting early kidney disease, especially in those with atypical muscle mass. The 2021 KDIGO eGFR equation uses both; if you can test both, do. If choosing one, cystatin-c is more robust across populations, but creatinine remains standard in Swedish vårdcentraler and is sufficient for monitoring trends in those with stable muscle mass.
Metformin itself doesn't damage kidneys, but it accumulates when GFR falls below 45 mL/min and can cause lactic acidosis (rare but serious). Your doctor won't raise creatinine, but you should measure GFR before starting and monitor it annually. If eGFR drops below 45, metformin is typically reduced or stopped. Always check renal function within 3–5 days of starting metformin or any dose increase to catch acute GFR drops.
Creatinine often rises modestly with age due to declining muscle mass and progressive GFR loss. However, a creatinine rise > 10–15 µmol/L over 1–2 years, or crossing into the cautionary range (105–130 µmol/L), warrants evaluation. Calculate eGFR and order cystatin-c. If eGFR is declining (> 3 mL/min/year in older adults), investigate causes: blood pressure control, glucose control, medication effects, and urinalysis for proteinuria or hematuria.
Intense exercise, particularly resistance training, can elevate creatinine transiently for 48 hours due to muscle microtrauma and increased creatinine production. Rest creatinine testing for at least 48 hours after intense or unfamiliar exercise, or note the timing. For routine monitoring, ensure your activity level is habitual (not just recovered from a hard training block) so creatinine reflects your baseline, not acute muscle stress.
Yes, acutely. ACE inhibitors and ARBs lower intraglomerular pressure, which can cause creatinine to rise 15–30% in the first weeks of treatment. This is usually benign and expected—it reflects a reduction in hyperfiltration. However, if creatinine rises > 30% or GFR drops sharply, the dose may need adjustment or a cause (dehydration, concurrent NSAID, volume depletion) should be ruled out. Measure creatinine and GFR within 3–5 days of starting or increasing dose, and again after 4 weeks. Stabilization after initial rise is reassuring.
